Navigation Links
Dey, L.P. Highlights Perforomist(R) Inhalation Solution Data to Be Presented at the International Conference of the American Thoracic Society
Date:5/14/2009

NAPA, Calif., May 14 /PRNewswire/ -- Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), announced today that data from two presentations highlighting the use of Perforomist(R) (formoterol fumarate) Inhalation Solution will be featured in poster format at the International Conference of the American Thoracic Society on May 19, 2009 in San Diego.

In one analysis, use of Perforomist Inhalation Solution, when added to maintenance tiotropium, resulted in improved pulmonary function, dyspnea (shortness of breath) and rescue medication use versus treatment with tiotropium alone. In a second study, patient satisfaction increased in those treated with Perforomist Inhalation Solution twice daily compared with ipratropium/albuterol metered-dose inhaler (MDI) four times daily.

Presentation Details

In COPD, Adding Nebulized Formoterol to Tiotropium Treatment Provides Added Benefits in Pulmonary Function, Dyspnea, and Rescue Medication Use: A Pooled Analysis; poster board # J51

Date: Tuesday, May 19, 2009

Poster viewing: 10:30 a.m. to 12:45 p.m. PT

Location: Area J (Sails Pavilion, Upper Level), San Diego Convention Center

Nebulized Formoterol Improved Efficacy and Increased Patient Satisfaction Compared with Ipratropium/Albuterol MDI; poster board # J50

Date: Tuesday, May 19, 2009

Poster viewing: 10:30 a.m. to 12:45 p.m. PT

Location: Area J (Sails Pavilion, Upper Level), San Diego Convention Center

About COPD (1)

COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual patien
'/>"/>

SOURCE Dey, L.P.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Stanford study highlights cost-effective method of lowering heart disease risks
2. REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
3. Other highlights in the September 11 JNCI
4. NEWSWEEK International Editions: Highlights and Exclusives, Oct. 1, 2007 Issue
5. Georgia Pecans Fit!: New Campaign Highlights Health Benefits, Recipes, Web Site
6. Highlights from the October 2007 Journal of the American Dietetic Association
7. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
8. NEWSWEEK International Editions: Highlights and Exclusives, OCT. 15, 2007 Issue
9. Study Highlights Impact of Chronic Conditions on Working America
10. Report highlights inadequate pandemic planning as a threat to EU security
11. World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Task Force Recommends Against Screening for Chronic Obstructive Pulmonary Disease Using Spirometry 2Health News:Task Force Recommends Against Screening for Chronic Obstructive Pulmonary Disease Using Spirometry 3Health News:Ronnie B. Martin, DO, FACOFP-dist. to be Inaugurated as the 55th President of the ACOFP (2008-2009) 2Health News:Ronnie B. Martin, DO, FACOFP-dist. to be Inaugurated as the 55th President of the ACOFP (2008-2009) 3Health News:Researchers identify new genetic marker for breast cancer 2Health News:Woman Sues DuPont and Asbestos Manufacturers After Developing Mesothelioma From Exposure to Asbestos in Husband's Work Clothes 2Health News:Cold Spring Harbor Protocols features high-throughput methods for analyzing gene activity 2Health News:Folic Acid in the Food Supply Reduces Birth Defects, but May Cause Extra Cancers, Reports the Harvard Women's Health Watch 2
Breaking Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Press conference schedule announced for TCT 2009 55559 1Press conference schedule announced for TCT 2009 55559 2Unique study isolates DNA from Linnaeus botanical collections 9719 1Phoenix Cardiovascular Surgeon David J Caparrelli M D Becomes Member of the Society for Vascular Surgery 55552 1Phoenix Cardiovascular Surgeon David J Caparrelli M D Becomes Member of the Society for Vascular Surgery 55552 2Phoenix Cardiovascular Surgeon David J Caparrelli M D Becomes Member of the Society for Vascular Surgery 55552 3